{
    "clinical_study": {
        "@rank": "5012", 
        "acronym": "GO-INF", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Formula", 
                "arm_group_type": "Experimental", 
                "description": "Infant formula with a novel probiotic CECT7210"
            }, 
            {
                "arm_group_label": "Standard Formula", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard infant formula without probiotics"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether an infant formula supplemented with a new\n      probiotic CECT7210, is effective in reducing the incidence of infections, specially the\n      gastrointestinal ones."
        }, 
        "brief_title": "The Effects of an Infant Formula Containing Probiotic CECT7210 on Gastrointestinal Health", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Gastrointestinal Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Gastrointestinal Diseases", 
                "Digestive System Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This a multicenter, controlled, randomized, prospective, parallel, double-blinded study to\n      evaluate the effect of an infant formula containing a new probiotic, Bifidobacterium longum\n      biovar infantis CECT7210, on the incidence of diarrhea in healthy infants born at term.\n      Infants will be randomized to take an standard infant formula or the infant formula with the\n      probiotic CECT7210 during 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Full-term healthy newborns (>= 37 weeks)\n\n          -  Birth weight between >=2.500g and <=4.500g)\n\n          -  Normal growth curve (between 3-97 percentiles)\n\n          -  0-60 days of age on enrolment\n\n          -  Maximum 30 days of breastfeeding\n\n          -  Exclusively infant formula on enrolment\n\n          -  Breastfeeding or infant formula with pre/probiotics feeding stopped 15 days before\n             enrolment\n\n          -  Parents or caregivers agree to exclude any source of prebiotics or probiotics during\n             the study\n\n          -  Parents or caregivers agree to follow-on the study 12 weeks\n\n          -  Informed consent signed ( Parent/Legal representative)\n\n        Exclusion Criteria:\n\n          -  Congenital illness or malformation that may affect infant feeding and /or normal\n             growth\n\n          -  Significant pre-natal or post-natal diseases\n\n          -  Infant's family history of atopy\n\n          -  Any pathology related to the immune or gastrointestinal system.\n\n          -  Suspected or known allergy to cow's milk protein\n\n          -  Infants receiving pre or probiotics within less than 15 days prior to enrolment\n\n          -  Infant's family who in the investigator's assessment cannot be expected to comply\n             with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "194", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096302", 
            "org_study_id": "GO-INF-010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Formula", 
                "description": "Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.", 
                "intervention_name": "Infant Formula with a novel probiotic CECT7210", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Standard Formula", 
                "description": "Standard formula without probiotics", 
                "intervention_name": "Standard formula", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Probiotics", 
            "Infant Formula", 
            "Microbiota", 
            "Bifidobacterium longum biovar infantis CECT7210", 
            "Growth"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Reus", 
                        "country": "Spain", 
                        "state": "Tarragona"
                    }, 
                    "name": "Hospital Sant Joan de Reus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Joan XXIII"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluar el Efecto de Una f\u00f3rmula Infantil Enriquecida Con el probi\u00f3tico CECT7210 Sobre la Incidencia de Infecciones Gastrointestinales", 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario La Paz, Madrid (Spain)", 
                "last_name": "Isabel Polanco, Professor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital Sant Joan de Reus, Reus, Spain", 
                "last_name": "Joaquin Escribano, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Joan XXIII de Tarragona, Tarragona, Spain", 
                "last_name": "Ricardo Closa, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Differences between diarrhea incidence amongst groups from baseline to 12th weeks.", 
            "measure": "Changes in diarrhea incidence", 
            "safety_issue": "No", 
            "time_frame": "At 4th, 8th, 12th weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096302"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Differences between rate of infections or duration amongst groups.", 
                "measure": "Changes in infections incidence", 
                "safety_issue": "No", 
                "time_frame": "At 4th, 8th, 12th weeks."
            }, 
            {
                "description": "Differences between faecal bacterial populations.", 
                "measure": "Changes in microbiota", 
                "safety_issue": "No", 
                "time_frame": "At 4th, 8th, 12th weeks"
            }, 
            {
                "description": "Differences between faecal IgAs amongst groups.", 
                "measure": "Changes in Immunoglobulin A secretor (IgAs)", 
                "safety_issue": "No", 
                "time_frame": "At  4th and 12th weeks"
            }, 
            {
                "description": "To evaluate gastrointestinal tolerability of both study formulas.", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "At 4th, 8th and 12th weeks"
            }, 
            {
                "description": "To compare anthropometric measurements between probiotic CECT7210 formula group and standard group.", 
                "measure": "Growth", 
                "safety_issue": "No", 
                "time_frame": "At 4th, 8th and 12th weeks"
            }
        ], 
        "source": "Laboratorios Ordesa", 
        "sponsors": {
            "collaborator": {
                "agency": "Harrison Clinical Research", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Laboratorios Ordesa", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}